TABLE 1.

Expression of programmed death-ligand 2 (PD-L2) in endometrial cancer (EC), peritumoral tissue, and normal endometrium.

	PD-L2
	High	Moderate	Low
Tumor	29/45 (64.44%)	11/45 (24.44%)	5/45 (11.11%)
Serous	18/26 (69.23%)	4/26 (15.38%)	4/26 (15.38%)
Clear cell	3/7 (42.85%)	3/7 (42.85%)	1/7 (14.28%)
Mixed	8/12 (66.66%)	4/12 (33.33%)	0/12 (0%)
Peritumoral tissue	1/4 (25%)	2/4 (50%)	1/4 (25%)
Normal endometrium	0/2 (0%)	1/2 (50%)	1/2 (50%)
FIGO stage
Stage I–II	13/17 (76.47%)	3/17 (17.64%)	1/17 (5.88%)
Serous	7/9 (77.77%)	1/9 (11.11%)	1/9 (11.11%)
Clear cell	1/2 (50%)	1/2 (50%)	0/2 (0%)
Mixed	5/6 (83.33%)	1/6 (16.66%)	0/6 (0%)
Stage III	7/16 (43.75%)	7/16 (43.75%)	2/16 (12.5%)
Serous	5/10 (50%)	3/10 (30%)	2/10 (20%)
Clear cell	0/2 (0%)	2/2 (100%)	0/2 (0%)
Mixed	2/4 (50%)	2/4 (50%)	0/4 (0%)
Stage IV	9/12 (75%)	1/12 (8.33%)	2/12 (16.66%)
Serous	6/7 (85.71%)	0/7 (0%)	1/7 (14.28%)
Clear cell	2/3 (66.66%)	0/3 (0%)	1/3 (33.33%)
Mixed	1/2 (50%)	1/2 (50%)	0/2 (0%)
Age
≤68	11/19 (57.89%)	5/19 (26.31%)	3/19 (15.79%)
>68	18/26 (69.23%)	6/26 (23.07%)	2/26 (7.69%)

Percentages of samples according to different clinicopathological characteristics.